An example of the importance of adequate target selection is Promiximab-DUBA, which binds to unknown specific isoforms of CD56 expressed only in some squamous cell lung cancer (SCLC) cell lines, leading to a limitation in performance for CD56-positive tumors with different isoforms [103]. This evidence concerns the gene NCAM1 and small cell lung carcinoma.